| Balance Sheets | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Cash and cash equivalents | 72,825 | 67,656 | ||
| Marketable securities | 39,779 | 41,816 | ||
| Income tax receivable | 1,802 | 9,922 | ||
| Other current receivables | 6,487 | 4,697 | ||
| Prepaid expenses | 3,533 | 2,481 | ||
| Total current assets | 124,426 | 126,572 | ||
| Property and equipment, net | 0 | 72 | ||
| Operating lease right-of-use assets | 0 | 629 | ||
| Income tax receivable | 0 | 1,029 | ||
| Investment in equity securities | 1,721 | 1,591 | ||
| Other assets | 600 | 600 | ||
| Total assets | 126,747 | 130,493 | ||
| Accounts payable | 1,334 | 4,012 | ||
| Accrued expenses and other current liabilities | 9,944 | 12,167 | ||
| Deferred collaboration cost recovery | - | 3,257 | ||
| Operating lease liability, current portion | 342 | 649 | ||
| Total current liabilities | 11,620 | 20,085 | ||
| Operating lease liability, net of current portion | 0 | 0 | ||
| Total liabilities | 11,620 | 20,085 | ||
| Preferred shares, no par value per share unlimited shares authorized as of september 30, 2025 and december 31, 2024 0 shares issued and outstanding as of september 30, 2025, and december 31, 2024 | 0 | 0 | ||
| Common shares, no par value per share unlimited shares authorized as of september 30, 2025 and december 31, 2024 42,985,755 and 42,510,708 shares issued and outstanding as of september 30, 2025 and december 31, 2024, respectively | 490,487 | 490,425 | ||
| Warrants | 60 | 43 | ||
| Additional paid-in capital | 85,893 | 84,533 | ||
| Accumulated other comprehensive income | 14 | -8 | ||
| Accumulated deficit | -461,327 | -464,585 | ||
| Total shareholders equity | 115,127 | 110,408 | ||
| Total liabilities and shareholders equity | 126,747 | 130,493 | ||
Repare Therapeutics Inc. (RPTX)
Repare Therapeutics Inc. (RPTX)